Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Estrogen receptor alpha (ERα) is a key target in ERα-positive breast cancer.
• Conventional ERα inhibitors targeting the ligand-binding domain (LBD) face challenges with drug resistance and cancer relapse.
• Emerging resistance necessitates novel therapeutic strategies targeting alternative ERα interaction sites.

Purpose of the Study:

• To review recent advancements in the development of ERα peptidomimetic antagonists.
• To highlight the potential of targeting ERα-coactivator interactions for overcoming drug resistance.

Main Methods:

• Literature review of recent research on ERα peptidomimetics.
• Analysis of studies focusing on ERα-coactivator interface modulation.
• Summary of drug discovery efforts in this area.

Main Results:

• Peptidomimetic modulators targeting the ERα-coactivator interface show promise.
• These modulators offer an alternative to traditional LBD inhibitors.
• Recent developments indicate progress in designing effective ERα peptidomimetic antagonists.

Conclusions:

• ERα peptidomimetic antagonists represent a promising therapeutic approach for drug-resistant breast cancers.
• Targeting the ERα-coactivator interface provides a viable strategy to overcome resistance mechanisms.
• Further research and development in ERα peptidomimetics are warranted for clinical translation.